DarDoc Research

GLP-1 Trial & Approval Tracker

Compare GLP-1 trial arms

Compare results within a trial or inspect the context behind results from different studies.

SURMOUNT-5

MounjaroWegovy injection

Without type 2 diabetes · 72 weeks · n=751

Open-label, randomised head-to-head trial using each participant’s maximum tolerated dose. Modified treatment-regimen analysis.

Mean body weight change at 72 weeks
  • Tirzepatide 10 or 15 mg−20.2%
  • Semaglutide 1.7 or 2.4 mg−13.7%
Published paper PubMed abstract NCT05822830

A direct comparison uses arms from the same trial. Switch to Two studies to inspect the context behind separate results.